Triumvira Immunologics, Inc.
About Triumvira Immunologics, Inc.
Triumvira is developing unique, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat a broad range of patients with cancer.
Our company is backed by a strong intellectual property portfolio and a management team with deep experience in cell therapy, oncology drug development and manufacturing. By accessing the latest industry technologies, we are pursuing highly innovative autologous and allogeneic approaches for our TAC-based programs. We have set out to help millions of patients defeat difficult-to-treat tumors through a potentially curative technology that naturally activates and regulates T cells.
If you want to work at the leading edge of cancer research, join us. We are looking for new talent with an eagerness to cure some of the most aggressive and life-threatening diseases. Ideal candidates have an equal amount of passion for making a difference in a patient’s life and ambition for becoming highly knowledgeable, established leaders.
20 articles with Triumvira Immunologics, Inc.
-
Triumvira Immunologics Announces Updated Data from Ongoing TACTIC‑2 Trial of TAC01-HER2 in Patients with HER2 Positive Solid Tumors
11/11/2022
Triumvira Immunologics today announced updated positive clinical data from its ongoing TACTIC‑2 Phase 1/2 trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 (HER2) positive solid tumors will be shared in a poster at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting from November 8-12, 2022.
-
Triumvira Immunologics Demonstrates Strength of Preclinical Research Pipeline for Gastric and Colorectal Cancers in Three Posters at SITC 2022
11/10/2022
Triumvira Immunologics today announced preclinical data for its investigational TAC-T cell therapies CLDN18.2-TAC T and GUCY2C-TAC T, and data on HER2-specific TAC-T products.
-
New Movers & Shakers took over the roles of chief executive officer, chief financial officer, chief medical officer and more at companies including Scenic Biotech, Biofrontera and X4 Pharmaceuticals.
-
Triumvira Immunologics to Present Clinical and Preclinical Updates at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
10/27/2022
Triumvira Immunologics today announced that it will present data from its ongoing clinical and preclinical programs at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held Nov. 10-12, 2022.
-
Triumvira Immunologics Appoints Life Sciences Industry Leader Robert Williamson as President and Chief Business Officer
10/25/2022
Triumvira Immunologics today announced the appointment of Robert Williamson as President and Chief Business Officer.
-
Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco
10/19/2022
Triumvira Immunologics announced a multi-year agreement with AmplifyBio to use its facilities in South San Francisco, Calif.
-
Triumvira Immunologics to Participate in Four Upcoming Healthcare Investor Conferences in October and November 2022
10/12/2022
Triumvira Immunologics today announced that Senior Management will participate in four upcoming healthcare investor conferences.
-
Triumvira Immunologics Presents Initial HER2-Positive Solid Tumor Clinical Data at ESMO
9/12/2022
Triumvira Immunologics announced positive initial clinical data from its ongoing TACTIC‑2 Phase 1/2 trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 positive solid tumors.
-
Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress
9/6/2022
Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will present interim clinical data from its ongoing TACTIC-2 clinical trial (NCT04727151) for TAC01-HER2 in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress.
-
Triumvira Immunologics to Present Two Posters Covering Ongoing Phase 1/2 Solid Tumor Trial and New Preclinical Gastric Cancer Data at AACR Annual Meeting 2022
4/10/2022
Triumvira Immunologics announced it will present two posters at the American Association for Cancer Research Annual Meeting, taking place April 8-13, 2022 in New Orleans.
-
Money on the Move: March 16-22
3/23/2022
Most major money moves this week were related to immune therapy companies, including rounds of funding for T cell therapies, allergy therapies and immunomodulation platforms. -
Triumvira Immunologics Completes Extension of Series A Financing, for Total Round of Approximately $100 Million
3/17/2022
Triumvira Immunologics today announced the completion of an extension of its Series A financing, bringing the total round to approximately $100 million.
-
Triumvira Immunologics Establishes Scientific Advisory Board
1/18/2022
Triumvira Immunologics today announced that the company formed its inaugural Scientific Advisory Board (SAB), comprising four leading scientists and physicians.
-
Triumvira Announces Data from Gastric Cancer Preclinical Study to be Presented at SITC Annual Meeting
11/13/2021
Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that do not require gene editing and co-opt the natural biology of T cells to treat patients with solid tumors, announced the presentation of preclinical data from its proof-of-concept study in gastric cancer.
-
Triumvira Appoints Oncology Industry Veteran Deyaa Adib, M.D., as Chief Medical Officer
10/28/2021
Triumvira Immunologics today announced that it has appointed Deyaa Adib, M.D., to serve as the company’s Chief Medical Officer, effective immediately.
-
Triumvira’s inaugural program is directed against HER2, a well-known tumor-associated antigen that is expressed in multiple tumors.
-
Triumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform
9/21/2021
Triumvira's T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, is manufactured using Lonza's Cocoon ® platform at the C3i Center Inc (C3i) in Montreal
-
Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial
9/20/2021
Triumvira Immunologics (“Triumvira”) today announced that the first patient has been dosed as part of the TACTIC-2 trial evaluating the company’s lead candidate, TAC01-HER2, an autologous T cell therapy for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors.
-
Triumvira Appoints Teresa McRoberts as Chief Financial Officer and Announces Senior Level Promotions
4/26/2021
Triumvira Immunologics (“Triumvira” or the “Company”), a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Teresa McRoberts as Chief Financial Officer. The Company also announced the promotion of Andreas Bader, Ph.D. to Chief Scientific Officer and Jon Irvin to Senior Vice President of Finance.
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.